Patch, gel, pill or pellet: does the route matter?
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Short answer
The route matters most for blood clot risk. Oral estrogen passes through the liver first and raises clotting proteins, and The Menopause Society notes clot risk is higher with oral forms. Patches, gels and sprays bypass that first pass. Vaginal estrogen treats local symptoms with minimal absorption. Pellets are compounded, not FDA approved, and cannot be removed.
Get urgent care if: you are on hormone therapy and develop
- Swelling, pain or redness in one calf or thigh.
- Sudden breathlessness, chest pain, or coughing blood.
- Sudden weakness or numbness on one side, facial droop, or difficulty speaking.
Route changes risk more than most patients are told. Oral estrogen is absorbed through the gut and passes through the liver before reaching the rest of the body, which increases production of clotting proteins. Transdermal estradiol delivered by patch, gel or spray enters the bloodstream directly and avoids that first pass. The Menopause Society lists blood clots as a risk of hormone therapy and states this applies especially to oral forms.
Choosing between oral and transdermal estrogen
Transdermal estradiol is usually preferred when clot risk is a consideration: higher body weight, migraine with aura, a family history of clotting, smoking, or an existing cardiovascular risk load. Oral estrogen remains reasonable for many women and is often cheaper and simpler. Patches need to be changed once or twice weekly and can irritate skin. Gels and sprays must dry before dressing and before skin contact with others, since estradiol transfers.
The progestogen part is not optional
Any woman with a uterus who takes systemic estrogen needs a progestogen to protect the endometrium. Unopposed estrogen increases endometrial cancer risk, which is the one boxed warning the FDA retained on systemic estrogen alone products in its November 2025 labelling action. Options include micronised progesterone taken at night, synthetic progestins, and a levonorgestrel intrauterine system in some cases. Low dose vaginal estrogen used for genitourinary symptoms delivers minimal systemic estrogen and does not require a progestogen.
Comparing the routes
| Route | How it is absorbed | Main consideration |
|---|---|---|
| Oral tablet | Gut, then liver first pass | Higher clot risk than transdermal |
| Patch | Through skin, twice weekly or weekly | Avoids liver first pass, skin irritation possible |
| Gel or spray | Through skin, daily | Avoids first pass, transfers to others until dry |
| Vaginal cream, tablet or ring | Local tissue, minimal systemic level | Treats dryness and painful sex, not hot flashes |
| Pellet | Implanted under the skin, releases for months | Compounded, not FDA approved, cannot be removed if levels run high |
Ask which route is being prescribed and why that one. If the answer is that the clinic only offers pellets, that is a business model rather than a clinical reason. The FDA states plainly that it does not verify the safety, effectiveness or quality of compounded drugs before they are marketed, and pellet doses cannot be adjusted or withdrawn once implanted. Start with an approved product, review at 12 weeks, and change route rather than abandoning treatment if the first choice does not suit you.
The clinical detail
Oral estrogens raise hepatic production of coagulation factors and sex hormone binding globulin because of first pass metabolism, which transdermal estradiol largely avoids. Standard transdermal estradiol patches deliver 0.025 to 0.1 mg per day. The 2019 Global Consensus Position Statement on testosterone therapy for women advises against any preparation producing supraphysiologic concentrations, naming pellets and injections specifically, and that principle is the same reason estradiol pellets are viewed with caution. Endometrial protection is required for any woman with an intact uterus on systemic estrogen, whatever the estrogen route.
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Sources
- Hormone Therapy. The Menopause Society
- Estradiol Transdermal System, full prescribing information. DailyMed, U.S. National Library of Medicine
- Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration
- Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Journal of Clinical Endocrinology and Metabolism. PMID 31498871
- HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. U.S. Food and Drug Administration
This library is educational and is not individual medical advice. Read our Editorial and Medical Review Policy.